Sign In   

OACS

Older Adult Cognitive Screener

Cecil R. Reynolds, PhD, and Erin D. Bigler, PhD

Pre-Order

Purpose:
Screens for neurocognitive impairment
Format:
Online administration and scoring via PARiConnect
Age range:
55 years to 90 years
Time:
Administer and score in 5-10 minutes
Qualification level:
B, S
B
A degree from an accredited 4-year college or university in psychology, counseling, speech-language pathology, or a closely related field plus satisfactory completion of coursework in test interpretation, psychometrics and measurement theory, educational statistics, or a closely related area; or license or certification from an agency that requires appropriate training and experience in the ethical and competent use of psychological tests.
S
A degree, certificate, or license to practice in a health care profession or occupation, including (but not limited to) the following: medicine, neurology, nursing, occupational therapy and other allied health care professions, physician's assistants, psychiatry, social work; plus appropriate training and experience in the ethical administration, scoring, and interpretation of clinical behavioral assessment instruments. Certain health care providers may be eligible to purchase selected "B" and "C" level instruments within their area of expertise. Specifically, relevant supervised clinical experience using tests (i.e., internship, residency, etc.) in combination with formal coursework ( i.e., Tests and Measurement, Individual Assessment, or equivalent) qualifies a health care provider to purchase certain restricted products. Any PAR Customer already qualified to purchase a "B" or "C" level product, is also qualified to purchase an "S" level product. If you are not already qualified to purchase a "B"or "C" level product from PAR, please download and complete the special Qualification Form for Medical and Allied Health Professionals. (You will need Adobe Acrobat to view.) Close

Coming soon! Preorder now. 
Patients with neurocognitive impairment (e.g., dementia) are often unreliable reporters of their own symptoms. A knowledgeable observer such as a family member, friend, or home health care nurse, can provide valuable insight into a patient's functioning. The OACS is a quick informant rating scale that helps professionals make decisions about a patient's mental status and determine the need for more in-depth testing.

Features and benefits

  • The only screening tool that maps directly onto the six principal domains of neurocognitive function defined in the DSM-5®: executive function, complex attention, language, perceptual–motor, social cognition, and learning and memory. 
  • Assesses activities of daily living separately from total neurocognitive impairment.
  • All-digital format ensures safe and convenient access to informant raters. 
  • Quickly indicates the need for follow-up testing.

Test structure

  • Administer and score in less than 10 minutes via PARiConnect. 
  • 21 items map onto the six principal domains of neurocognitive functioning with two additional items that assess validity and orientation. An additional unscored item measures whether current behaviors reflect change over time.
  • Informants rate frequency of observed behavior on a scale of "Daily," "Weekly" "Monthly," and "Yearly or Never."
  • The OACS Score Report includes the OACS Total T score, which indicates potential impairment, and an optional Domains of Concern profile to help you visually compare performance across the neurocognitive domains.
  • OACS Change Report tracks change over time. 

Technical information

  • Normative sample consisted of a CASE standardization subsample of 800 older adults matched to 2018 U.S. Census data for gender, age, educational level, and ethnicity.
  • Internal consistency reliability for the overall standardization and dementia clinical samples were .88 and .92, respectively. 
  • Using the recommended ranges for risk of impairment, 91.7% of the dementia sample earned an OACS Total score in an elevated risk of impairment range (moderate or severe) compared to 12.5% of the matched-case control sample and 17.2% of the standardization sample.